logo

Alopecia areata is an autoimmune disease resulting in hair loss that is usually in one or more coin-shaped patches on the face, scalp or other areas of the body that grows hair.

We are recruiting subjects aged 18 to 65 years (inclusive) with Alopecia Areata, to participate in a research study that evaluates the safety of an investigational study drug (IMG-007-202), and how participants with Alopecia Areata react to the study drug when given multiple times.

The research will involve two groups of people who will receive different amounts of a medication called IMG-007. The first group, called Cohort 1, will have six participants who will receive three IV (Intravenous) infusions of IMG-007, each containing 300 mg of the medication, over a period of 4 weeks. The second group, called Cohort 2, will have 24 participants who will receive three IV (Intravenous) infusions of IMG-007, each containing 600 mg of the medication, over a period of 4 weeks.

Each participant will go through three phases during the study. The first is a screening phase that can last up to 5 weeks, the second phase is a 16-week treatment phase, and finally there be an 8-week follow-up phase to monitor the participants progress after the treatment period.

This study will last a period of up to 29 weeks and includes 9 visits + 2 follow up; Visits take approximately 4-5 hrs for drug administration days and 2-3 hours for other visits.

Blood samples will be collected from all participants at each visit. 

Skin biopsies (a small piece of skin) will be taken during the study.

Compensation may be provided. Participation in this study will come at no cost to you.


Visits
Drug administered on which days
Total
Length
Procedures
Study Length
Days
Day 1,15 and 29
Total
9 visits + 2 follow up
Length
Up to 6 hours Day 1, 15 and 29 and other visits up to 2 hours
Procedures
Blood samples, skin biopsy and medical photography
Study Length
29 weeks
Summary
We are currently recruiting patients with alopecia areata ages 18 to 65 years old for a study that investigates the safety of multiple doses of IMG-007 IV infusion.
Condition
Alopecia areata
Treatment
IMG-007

There are 14 locations for this study

Acclaim dermatology

Acclaim dermatology

Sugar Land, Texas, 77479, United States
Options Research Group

Options Research Group

West Lafayette, Indiana, 47906, United States
Northwest Arkansas Clinical Trials Center

Northwest Arkansas Clinical Trials Center

Rogers, Arkansas, 72758, United States
Skin Search of Rochester, Inc.

Skin Search of Rochester, Inc.

Rochester, New York, 14623, United States
Alliance Clinical Research of Tampa

Alliance Clinical Research of Tampa

Tampa, Florida, 33615, United States
Dermatology Specialists of Spokane

Dermatology Specialists of Spokane

Spokane, Washington, 99202, United States
Innovaderm Research Inc.

Innovaderm Research Inc.

Montréal, Quebec, H2X 2V1, Canada
SKiN Health

SKiN Health

Cobourg, Ontario, K9A0Z4, Canada
Torrance Clinical Research Institute Inc

Torrance Clinical Research Institute Inc

Lomita, California, 90503, United States
Guelph Dermatology Research

Guelph Dermatology Research

Guelph, Ontario, N1L0B7, Canada
Centre de Recherche Saint-Louis

Centre de Recherche Saint-Louis

Québec, Quebec, G1W 4R4, Canada
Dawes Fretzin Clinical Research Group, LLC - Indianapolis

Dawes Fretzin Clinical Research Group, LLC - Indianapolis

Indiana, Indiana, 46250, United States
SimcoDerm Medical and Surgical Dermatology Center

SimcoDerm Medical and Surgical Dermatology Center

Barrie, Ontario, L4M 7G1, Canada
Great Lakes Research Group, Inc.

Great Lakes Research Group, Inc.

Bay City, Michigan, 48706, United States
Rectangle 191

Are you a researcher or representative of a clinical site?

Join our network of clinical sites and be at the forefront of innovation in clinical research.